Merck & Co. Sues Teva to Block Copies of Dificid Antibiotic

Merck said Teva’s proposed generic version of an antibiotic treatment for Clostridium difficile-associated diarrhea infringes five patents for Dificid.

• Merck is seeking a court order blocking copies until after the patents have expired and to collect cash compensation if copies are made before then, according to complaint filed Thursday in federal court in Newark, New Jersey
• One patent expires in January 2024, and four patents expire in January 2028: FDA Orange Book
• Merck filed a lawsuit against Teva in 2015 over the same patents; that case, also in New Jersey, is pending
  • Merck filed the latest complaint ...